Metropolitan Life Insurance CO Humanigen, Inc Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.66 - $8.22 $55,836 - $125,404	-15,256 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$5.93 - $17.83 $90,468 - $272,014	15,256 New	15,256 $90,000
Q3 2021 Mar 30, 2023	BUY	$5.93 - $17.83 $7,869 - $23,660	1,327 Added 9.53%	15,256 $90,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $7,869 - $23,660	1,327 Added 9.53%	15,256 $90,000
Q2 2021 Jun 21, 2023	BUY	$13.54 - $22.74 $188,598 - $316,745	13,929 New	13,929 $242,000
Q2 2021 Mar 30, 2023	BUY	$13.54 - $22.74 $188,598 - $316,745	13,929 New	13,929 $242,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $188,598 - $316,745	13,929 New	13,929 $242,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.